# Zepbound vs Mounjaro: When the Same Drug Has Two Brand Names

Source: https://www.dietglp.com/blog/zepbound-vs-mounjaro/
Published: 2026-01-18
Keywords: zepbound vs mounjaro, tirzepatide brands, zepbound dose

**TL;DR:** Zepbound and Mounjaro are identical molecules (tirzepatide) made by Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurance coverage is the most likely deciding factor.

If Wegovy is to Ozempic what Zepbound is to Mounjaro: same drug, two labels, regulatory and insurance reasons for the split.

## The molecule

Both are **tirzepatide**, manufactured by Eli Lilly. Same dose strengths (2.5, 5, 7.5, 10, 12.5, 15 mg). Same titration schedule. Same once-weekly subcutaneous injection.

## Why two brands exist

Eli Lilly first won FDA approval for tirzepatide as a type 2 diabetes drug in 2022 under the brand name **Mounjaro**. The clinical trial program for obesity (SURMOUNT-1, SURMOUNT-2) finished a year later, and in late 2023 the FDA approved tirzepatide for chronic weight management under the brand name **Zepbound**. In December 2024 Zepbound also gained an approval for moderate to severe obstructive sleep apnea in adults with obesity, which our [Zepbound for sleep apnea guide](/blog/zepbound-sleep-apnea/) explains.

The reason for two brand names is purely commercial: it lets Lilly negotiate different prices and rebates with insurers depending on the indication.

## What is different in practice

| | **Zepbound** | **Mounjaro** |
|---|---|---|
| Molecule | Tirzepatide | Tirzepatide |
| FDA approval | Chronic weight management | Type 2 diabetes |
| Insurance coverage | Often covered for BMI ≥30 (or ≥27 with comorbidity) | Often covered for diabetes only |
| List price | Slightly different | Slightly different |
| Pen design | Identical mechanism | Identical mechanism |

That is essentially the entire list. The molecule is the same, the side-effect profile is the same, the muscle-loss risk is the same, and the protein floor you need to hit on either one is the same.

## When patients switch

Patients commonly switch between the two when:

- Insurance coverage changes
- A diabetic loses enough weight that their HbA1c normalizes (and Mounjaro coverage gets reviewed)
- Local pharmacy supply favors one brand over the other

The transition is seamless: your prescriber writes for the equivalent dose strength on the new pen, and you continue.

## Bottom line

If you have a choice, take whichever your insurance covers. If you are paying out of pocket, both list-price equivalents land in roughly the same range, and Lilly's direct-pay programs (LillyDirect) often offer the best out-of-pocket price on Zepbound. The clinical experience is identical.